DK1068870T3 - Antitumormidler - Google Patents

Antitumormidler

Info

Publication number
DK1068870T3
DK1068870T3 DK99910779T DK99910779T DK1068870T3 DK 1068870 T3 DK1068870 T3 DK 1068870T3 DK 99910779 T DK99910779 T DK 99910779T DK 99910779 T DK99910779 T DK 99910779T DK 1068870 T3 DK1068870 T3 DK 1068870T3
Authority
DK
Denmark
Prior art keywords
active ingredients
antitumor
stilbene derivative
antitumor activity
antitumor agent
Prior art date
Application number
DK99910779T
Other languages
Danish (da)
English (en)
Inventor
Yoshihiro Morinaga
Yukio Nihei
Yasuyo Suga
Manabu Suzuki
Kazuo Ohishi
Akira Okano
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Application granted granted Critical
Publication of DK1068870T3 publication Critical patent/DK1068870T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99910779T 1998-04-03 1999-03-29 Antitumormidler DK1068870T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10870898 1998-04-03
JP22984398 1998-08-14

Publications (1)

Publication Number Publication Date
DK1068870T3 true DK1068870T3 (da) 2006-10-02

Family

ID=26448545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99910779T DK1068870T3 (da) 1998-04-03 1999-03-29 Antitumormidler

Country Status (19)

Country Link
US (6) US6462087B1 (pt)
EP (1) EP1068870B1 (pt)
JP (3) JP4470321B2 (pt)
KR (1) KR100598474B1 (pt)
CN (1) CN1140272C (pt)
AT (1) ATE328599T1 (pt)
AU (1) AU747599C (pt)
BR (1) BR9909393A (pt)
CA (1) CA2326761C (pt)
DE (1) DE69931766T2 (pt)
DK (1) DK1068870T3 (pt)
ES (1) ES2267255T3 (pt)
HU (1) HUP0102521A3 (pt)
IL (1) IL138723A (pt)
NO (1) NO328704B1 (pt)
NZ (1) NZ507221A (pt)
PT (1) PT1068870E (pt)
RU (1) RU2215525C2 (pt)
WO (1) WO1999051246A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
NZ507221A (en) * 1998-04-03 2003-04-29 Ajinomoto Kk Antitumor agent
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20050209310A1 (en) * 2000-12-22 2005-09-22 Chaplin David J Methods for modulating tumor growth and metastasis
CN100462354C (zh) * 2001-01-18 2009-02-18 天济药业（深圳）有限公司 治疗免疫疾病的新的1,2-二苯基乙烯衍生物
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
ATE489080T1 (de) * 2001-06-25 2010-12-15 Ajinomoto Kk Antitumorale mittel
KR20030018800A (ko) * 2001-08-31 2003-03-06 주식회사 프로메디텍 시토크롬 피450 1비1 억제활성을 갖는 페닐환 유도체 및약학적으로 허용가능한 그의 염, 그의 제조방법 및 이를함유하는 조성물
CN1744892A (zh) * 2003-02-04 2006-03-08 株式会社益力多本社 乳癌耐性蛋白(bcrp)抑制剂
ES2528669T3 (es) * 2003-04-08 2015-02-11 Progenics Pharmaceuticals, Inc. Formulaciones farmacéuticas que contienen metilnaltrexona
BRPI0607688A2 (pt) * 2005-02-17 2009-09-22 Synta Pharmaceuticals Corp método para inibir a polimerização de tubulina em uma célula; método para tratar ou prevenir um distúrbio proliferativo em um indivìduo; método para bloquear, ocluir ou de outro modo romper o fluxo sangüìneo na neovasculatura; composto; composição farmacêutica e uso do referido método e composto
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
AU2006220682B2 (en) * 2005-03-07 2012-05-31 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
US8168661B2 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
PE20090700A1 (es) * 2007-03-29 2009-07-13 Progenics Pharm Inc Compuestos heterociclicos como antagonistas del receptor opioide periferico
PT2139890E (pt) * 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
MX2009010550A (es) * 2007-03-29 2009-12-14 Progenics Pharm Inc Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas.
US8095816B1 (en) 2007-04-05 2012-01-10 Marvell International Ltd. Processor management using a buffer
US8443187B1 (en) 2007-04-12 2013-05-14 Marvell International Ltd. Authentication of computing devices in server based on mapping between port identifier and MAC address that allows actions-per-group instead of just actions-per-single device
US8321706B2 (en) 2007-07-23 2012-11-27 Marvell World Trade Ltd. USB self-idling techniques
SI2219451T1 (sl) 2007-11-21 2015-02-27 Oxigene, Inc. Postopek za zdravljenje hematopoetskih neoplazem
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
JP5647098B2 (ja) 2008-03-21 2014-12-24 ザ ユニヴァーシティー オヴ シカゴ オピオイド拮抗薬とｍＴＯＲ阻害薬を用いた治療
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010056378A2 (en) 2008-11-14 2010-05-20 Histogen, Inc. Extracellular matrix compositions for the treatment of cancer
FR2945210B1 (fr) * 2009-05-07 2011-07-01 Sanofi Aventis Combinaison antitumorale comprenant l'ave8062 et le sorafenib
FR2953518B1 (fr) 2009-12-03 2012-01-20 Sanofi Aventis Procede de preparation d'un derive de combretastatine
PE20130312A1 (es) 2010-06-18 2013-03-26 Sanofi Sa Una combinacion antitumoral que comprende ombrabulina, un derivado de taxano y un derivado de platino
EP2481404A1 (en) 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2397135A1 (en) 2010-06-18 2011-12-21 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
EP2407161A1 (en) 2010-07-13 2012-01-18 Sanofi An antitumoral combination comprising ombrabulin and bevacizumab
FR2968557A1 (fr) 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
US8664276B2 (en) 2011-01-28 2014-03-04 University Of Kentucky Research Foundation Stilbene analogs and methods of treating cancer
EP2724156B1 (en) 2011-06-27 2017-08-16 The Jackson Laboratory Methods and compositions for treatment of cancer and autoimmune disease
US9141394B2 (en) 2011-07-29 2015-09-22 Marvell World Trade Ltd. Switching between processor cache and random-access memory
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
FR2978662A1 (fr) * 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
US9436629B2 (en) 2011-11-15 2016-09-06 Marvell World Trade Ltd. Dynamic boot image streaming
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US9575768B1 (en) 2013-01-08 2017-02-21 Marvell International Ltd. Loading boot code from multiple memories
US10201623B2 (en) 2013-03-15 2019-02-12 Memorial Sloan Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
US9458086B1 (en) 2013-07-03 2016-10-04 University Of South Florida (A Florida Non-Profit Corporation) Compositions and methods for adipocyte modulation
EP3337495A4 (en) 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN107311846B (zh) * 2017-07-25 2022-05-13 上海华理生物医药股份有限公司 偕二氟乙基取代的二苯乙烯和二苯乙烷类衍生物及其制备方法和应用
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
CN112225673B (zh) * 2020-11-13 2022-08-02 义乌市华耀医药科技有限公司 氨基康普立停衍生物及其应用
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588505A5 (pt) * 1972-06-08 1977-06-15 Research Corp
JPS56103192A (en) * 1980-01-18 1981-08-18 Yoshinori Kitani Novel platinum complex
US4935450A (en) * 1982-09-17 1990-06-19 Therapeutical Systems Corporation Cancer therapy system for effecting oncolysis of malignant neoplasms
CA1338645C (en) * 1987-01-06 1996-10-15 George R. Pettit Isolation, structural elucidation and synthesis of novel antineoplastic substances denominated "combretastatins"
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
US5561136A (en) * 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
GB9106177D0 (en) * 1991-03-22 1991-05-08 Aston Molecules Ltd Substituted diphenylethylenes and analogues or derivatives thereof
US5525622A (en) * 1991-08-28 1996-06-11 Bayer Aktiengesellschaft Substituted pyrazolines
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5844001A (en) * 1993-02-26 1998-12-01 Research Development Foundation Combination platinum chemotherapeutic/antiestrogen therapy for human cancers
US5409690A (en) * 1993-06-23 1995-04-25 Chemex Pharmaceuticals, Inc. Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
US5731353A (en) * 1993-09-08 1998-03-24 Ajinomoto Co., Inc. Stilbene derivatives and pharmaceutical compositions containing them
TW325458B (en) * 1993-09-08 1998-01-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions comprising the same for anti-cancer
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
JP3163391B2 (ja) 1995-03-07 2001-05-08 味の素株式会社 スチルベン誘導体及びそれを含有する制癌剤
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
WO1997008184A1 (en) * 1995-08-30 1997-03-06 Arch Development Corporation Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators
EA002630B1 (ru) 1997-02-05 2002-08-29 Фармация Энд Апджон Компани Способ получения липидных комплексов или липосом водонерастворимого диаминоциклогександикарбоксилата платины
NZ507221A (en) * 1998-04-03 2003-04-29 Ajinomoto Kk Antitumor agent
CZ292170B6 (cs) 1998-08-14 2003-08-13 Pliva-Lachema A.S. Farmaceutická kompozice s protinádorovým účinkem na bázi carboplatiny
GB9903403D0 (en) * 1999-02-16 1999-04-07 Angiogene Pharm Ltd Substituted stilbene compounds with vascular damaging activity
GB9918912D0 (en) * 1999-08-12 1999-10-13 Angiogene Pharm Ltd New stilbenes with vascular damaging activity
JP2004523517A (ja) * 2000-12-22 2004-08-05 ブリストル−マイヤーズ スクイブ カンパニー 腫瘍増殖および転移を調節するための方法
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
ATE489080T1 (de) * 2001-06-25 2010-12-15 Ajinomoto Kk Antitumorale mittel

Also Published As

Publication number Publication date
CA2326761C (en) 2008-02-19
DE69931766T2 (de) 2007-05-31
KR100598474B1 (ko) 2006-07-11
US7973076B2 (en) 2011-07-05
AU747599C (en) 2003-06-05
NZ507221A (en) 2003-04-29
HUP0102521A3 (en) 2003-08-28
CN1140272C (zh) 2004-03-03
US20020193362A1 (en) 2002-12-19
EP1068870A4 (en) 2003-02-12
CN1303294A (zh) 2001-07-11
US20050281892A1 (en) 2005-12-22
JP4470321B2 (ja) 2010-06-02
ATE328599T1 (de) 2006-06-15
AU2960799A (en) 1999-10-25
PT1068870E (pt) 2006-10-31
NO20004911L (no) 2000-12-04
JP5056816B2 (ja) 2012-10-24
US20020193434A1 (en) 2002-12-19
WO1999051246A1 (fr) 1999-10-14
JP2009275052A (ja) 2009-11-26
IL138723A0 (en) 2001-10-31
US6462087B1 (en) 2002-10-08
KR20010042399A (ko) 2001-05-25
JP5120368B2 (ja) 2013-01-16
US7655696B2 (en) 2010-02-02
NO20004911D0 (no) 2000-09-29
HUP0102521A2 (hu) 2001-10-28
ES2267255T3 (es) 2007-03-01
CA2326761A1 (en) 1999-10-14
US20100069486A1 (en) 2010-03-18
AU747599B2 (en) 2002-05-16
US20090093540A1 (en) 2009-04-09
RU2215525C2 (ru) 2003-11-10
EP1068870A1 (en) 2001-01-17
DE69931766D1 (de) 2006-07-20
BR9909393A (pt) 2000-12-26
JP2010053156A (ja) 2010-03-11
US6992106B2 (en) 2006-01-31
NO328704B1 (no) 2010-04-26
IL138723A (en) 2005-11-20
EP1068870B1 (en) 2006-06-07

Similar Documents

Publication Publication Date Title
DK1068870T3 (da) Antitumormidler
BR0308854A (pt) Benzazolas substituìdas e seus usos como inibidoras de quinase raf
DE69535805D1 (de) Neue Carbamate- und Harnstoffderivate als Mittel gegen Multidrugresistenz
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
HK1091481A1 (en) Therapeutic agents useful for treating pain
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
BR9814923A (pt) Método para tratamento de doença de alzheimer
ES2192832T3 (es) Uso de compuestos macrolidos para tratar glaucoma.
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
ES2133324T3 (es) Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso.
ATE338553T1 (de) Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
IT1264530B (it) Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
ATE530184T1 (de) Piperazinon-verbindungen als tumor- und krebsbekämpfende wirkstoffe
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
WO2002098362A3 (en) Use of rank antagonists to treat cancer
MXPA04001328A (es) Productos en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otros ingredientes activos, y su uso.
IT1304183B1 (it) Complessi di proantocianidina a2 con fosfolipidi come agentiantiaterosclerotici.
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
DE69113162D1 (de) Antiallergische Mischung.
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
LV11593A (lv) Dimetikona pielietojums aizcietejumu arstesana
PT862433E (pt) Composicao farmaceutica espumante topica para o tratamento de dermatoses induzidas por pityrosporum oval
DE60203895D1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie
ATE346080T1 (de) Steroid-verbindungen mit anti-tumoraler wirkung